In a study of patients with type 2 diabetes at high cardiovascular risk, metformin use decrease the risk for all-cause mortality but had no significant effect on a composite end point of cardiovascular death, myocardial infarction, or ischemic stroke.
Jody A. CharnowEditor
Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.